Dual orexin receptor antagonists(DORAs)are a novel class of anti-insomnia drugs that suppress excessive arousal signals,counteract excessive brain activity in insomnia patients,and help alleviate insomnia symptoms.Daridorexant,a new type of DORAs,has been approved for the treatment of adult insomnia in multiple countries.Daridorexant significantly addresses the unmet clinical needs of traditional anti-insomnia drugs and their similar mechanisms,such as reducing the occurrence of adverse reactions such as falls and residual effects the next day;it also offers advantages in terms of daytime functional recovery,elderly population,and long-term application compliance.This article reviews the effectiveness and safety of daridorexant based on completed Phase Ⅰ～Ⅲ clinical studies,providing references for its further development and clinical application.
维普
万方数据